9^th World Congress On Cardiology and Heart Failure

Novel Pharmacological Therapies in Heart Failure

Recent advances in pharmacology have introduced new therapies that improve survival, reduce hospitalizations, and enhance quality of life in heart failure patients.

Key Highlights:

• Sodium-glucose cotransporter 2 inhibitors: Improve cardiac outcomes beyond glycemic control.
• Angiotensin receptor-neprilysin inhibitors: Reduce mortality and hospitalizations in reduced ejection fraction heart failure.
• Selective myosin modulators: Enhance cardiac contractility without increasing oxygen demand.
• Anti-inflammatory agents: Target systemic inflammation contributing to heart failure progression.
• Tailored therapy: Personalized medication combinations based on patient profile optimize outcomes.

Emerging pharmacological treatments are reshaping heart failure management by addressing multiple pathophysiological pathways and improving patient prognosis.